Pesticidal compositions and processes related thereto
US-2017158598-A1 · Jun 8, 2017 · US
Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
US9051250B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9051250-B2 |
| Application number | US-201414165448-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 27, 2014 |
| Priority date | Nov 28, 2007 |
| Publication date | Jun 9, 2015 |
| Grant date | Jun 9, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a subject with cancer, the method comprising administering to the subject an effective amount of a compound represented by the following Structural Formula: wherein at least 70% by weight of the compound is crystal habit 2 of a single crystalline form Form A of the compound; and wherein the crystal habit 2 of the single crystalline f…
Assignees
Inventors
Classifications
- C07C327/56Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9051250B2 cover?
- At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises adm…
- Who is the assignee on this patent?
- Synta Pharmaceuticals Corp
- What technology area does this patent fall under?
- Primary CPC classification C07C327/56. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).